Our CSO, Hiroaki Kato, has been reappointed as Visiting Associate Professor at Chiba University Hospital.

Our CSO, Hiroaki Kato, has been re-elected as a councilor of the Japanese Ophthalmological AI Society.

Our CSO, Hiroaki Kato, has been reappointed as Clinical Associate Professor of Tokyo Medical and Dental University.

Our CSO, Hiroaki Kato, has been reappointed as a part-time lecturer at Yokohama City University.

Our CSO, Hiroaki Kato, has been reappointed as a part-time lecturer at Graduate School at Tohoku University.

Aillis ranked third in Nikkei Digital Health's ranking of the hottest venture companies in the digital health field.

Our CSO, Hiroaki Kato, has been appointed as a member of the Innovation Promotion Committee of the Japanese Ophthalmological Society.

Aillis, a medical AI venture company, implemented a credit-accredited internship program with Tokyo Medical and Dental University.

Aillis, an AI medical device venture company, has been selected by METI as a "J-startup company" for 2019.

Aillis, an AI medical device venture company, has raised 1.25 billion yen in funding.

Aillis got a “First class medical devices marketing license”, and became a “medical device manufacturer”.

Aillis moved to a new office.

Aillis has been certified as a partner company of the NVIDIA Inception Program.

The proposal for "Influenza test method using artificial intelligence technology for highly accurate and early diagnosis" was accepted by NEDO.

Our CSO, Hiroaki Kato, published Iryo 4.0(Medical care 4.0) from Nikkei BP.

Aillis won AITC President Award at AI Business Idea Contest held by AIST and OCCI.